Companies: 10,795·Total market cap: $144.5T
Cross Country Healthcare, Inc.

Cross Country Healthcare, Inc.

CCRNNASDAQHealthcare● Active
$13.18
+$0.00(+0.00%)
Market Cap$426144986
P/E Ratio
52W High$14.99
52W Low$7.43
Overview

Cross Country Healthcare, Inc. (CCRN) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

ccrn · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 14 Wall Street analysts in the past 3 months

SellBuy

Hold

14 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
2
Hold
12
Sell
0
Strong Sell
0
Total: 14 · Buy rate: 14.3%

12-Month Price Target

High

$14.00

Consensus

$11.00

-16.7% upside

Low

$9.00

Median: $10.5 · Last Close: $13.20

The Cross Country Healthcare, Inc. (CCRN) analyst consensus is Hold, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month CCRN price target is $11.00, representing -16.7% upside from the current price of $13.20.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $11 (-16.7%)

Consensus Target

$11.00

-16.7% upside

High Target

$14

6.1%

Low Target

$9

-31.8%

Current Price

$13.20

as of today

Based on analyst price targets, the CCRN stock price prediction for the next 12 months ranges from $9 to $14. The consensus CCRN price forecast of $11.00 implies -16.7% upside from the current price of $13.20.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$13.220.12%

1-day model range: $13.08–$13.35. Peak: $13.35 (+0.12%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$10-25.4%
2028$8-35.8%
2029$8-40.7%
2030$7-43.3%
2031-44.6%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

93%7%0%
13Buy
1Neutral
0Sell
RSI (14)69.2Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · CCRN · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$13.16BUY
MA 10$13.12BUY
MA 20$13.11BUY
MA 50$11.30BUY
MA 100$10.16BUY
MA 200$10.80BUY
Current $CCRN · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$13.16BUY
EMA 10$13.10BUY
EMA 20$12.78BUY
EMA 50$11.71BUY
EMA 100$10.98BUY
EMA 200$11.30BUY
Current $CCRN · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Truist Securities2026-05-11
Maintains
HoldHold
Benchmark2026-05-08
Downgrade ↓
BuyHold
Wedbush2026-05-07
Downgrade ↓
OutperformNeutral
Wedbush2026-03-19
Upgrade ↑
NeutralOutperform
Benchmark2026-03-05
Upgrade ↑
HoldBuy
UBS2025-12-09
Maintains
NeutralNeutral
Barrington Research2025-06-17
Maintains
Market PerformMarket Perform
UBS2025-05-13
Maintains
NeutralNeutral
Barrington Research2025-03-14
Maintains
Market PerformMarket Perform
JMP Securities2025-02-06
Maintains
Market PerformMarket Perform

Wall Street analysts have recently issued updated ratings on Cross Country Healthcare, Inc. (CCRN) stock. Of the recent 77 rating actions, 10 were upgrades and 14 were downgrades. 14 analysts currently cover CCRN.

Analyst Recommendation Trends

Buy ratings00
Hold ratings13↑ +2
Sell ratings00

CCRN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$980M

↓ 8.8% YoY

Revenue Next Year

$1.0B

↑ 4.5% YoY

EPS This Year

$0.09

EPS Next Year

$0.25

↑ 159.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CCRN EPS of $0.09 for the current fiscal year, based on estimates from 5 analysts. The CCRN revenue forecast is $980M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The CCRN stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CCRN price target is $11.00 (-16.7% upside), with an analyst consensus of Hold.

The CCRN short-term stock prediction for tomorrow is $13.22 (+0.12%). The CCRN stock price prediction for 2027 estimates an average of $10. The CCRN stock prediction for 2030 projects a range of $7–$8.

Cross Country Healthcare, Inc. trades on NASDAQ under the ticker CCRN. The CCRN stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 14% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

CCRN forecast · 8 questions

According to 14 Wall Street analysts, the average 12-month CCRN price target is $11.00, with a high forecast of $14.00 and a low of $9.00. The median price target is shown in the chart above when available. This implies -16.7% potential upside from the current price of $13.20.

CCRN price targetWhat is CCRN price targetCCRN analyst price targetCCRN 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.